• ● Faculty and Staff
Xing-Jie Liang
Deputy Director of the Laboratory of Biological Effects of Nanomaterials and Nanosafety
Academic title:
Postal Code:
Subject categories:
Mailing Address:
No.11,Beiyitiao Zhongguancun Beijing,china


  Dr. Liang graduated at Department of Microbiology, College of Life Science, NanKai University and got Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and a principal investigator at Division of Nanomedicine and Nanobiology, National Center for Nanoscience and Technology of China. Dr. Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, and member of American Society of Cell Biology. Dr. Liang is current editorial board member of Biophysics Report, Advances in Nano Research, current nanoscience, Biomaterials Research,Theranosticsand guest editor of Biotechnology Advances. 

  The current researches include three topics ongoing in the laboratory.  

  1. Nanochemotherapy: Nanotechnology to improve the bioavailability and efficiency as well as to decrease toxicity of chemocompounds; nanoadjuvants 

  2. Nanobiomedicinal Therapy: Nanomaterials to increase the bio-drugs( genes or proteins) delivery by targeted and controllable release 

  3. Nanobiotechnology: Nanostructures to solve the medicinal or pharmaceutical toughest problems (MDR, stem cells development etc) 

  In addition, another topic on nanoimaging is also one of the most interested fields in his group.  

  4. Nanoimaging:  Nanopharmaceuticals ADMET in vivo by various techniques (Nano SPECT/CT, Acoustic ultrasound, In vivo Imaging, MRI, Bio-TEM etc) 

  His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and developing novel strategies to increase therapeutic effect on cancers and AIDS. Improved drug delivery efficiency for prevention/treatment of AIDS and cancers are under investigation in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanomedicine. Most protocols are employed for delivering therapeutic compounds to actively target cells or tissues in vivo to enhance drug safety and efficacy. Dr. Liang’s current research activities include: Nanotherapeutics for cancer treatment; Nanotherapeutics for AIDS treatment; Nanoparticle interactions with biological membranes; Nanotechnology to circumvent multidrug resistance of cancer; Nanobiomedicine and nanosafety; Nanotechnology to improve the vaccine immunogenicity; Nanomaterials imaging in vitro and in vivo.  





2004 2005 and 2006 "Fellows Award for Research Excellence" National Institute of Health, USA. Adjuvant Professor of Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Biomedical Engineering. 


Publications*, correspondence author  

  1. Liu J, Huang Y, Kumar A, Tan A, Jin J, Mozhi A, Liang XJ*. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances (2013), DOI: 10.1016/ j.biotechadv. 2013.11.009.

  2. Xue X, Hall M, Zhang Q, Wang P, Gotteman MM, Liang XJ *. Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein. ACS Nano. 2013. DOI10.1021/nn405004f.

  3. Xue X, Zhao Y, Dai L, Zhang X, Hao X, Huo S, Liu J, Liu C, Kumar A, Zou,G* Liang XJ*. Spatiotemporal Drug Release Visualized Through a Drug Delivery System with Tunable Aggregation-Induced Emission. Advanced Materials. 2013. DOI: 10.1002/adma.201302365.Highlighted in "Noteworthy Chemistry" by American Chemical Society (ACS). December 16, 2013.

  4. Han L.; Zhao J.; Liu J.; Duan X.; Wei Y.; Liang XJ*. A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection. Biomaterials. 2013. DOI: jbmt26398.

  5. Xu X, Zhao Y, Xue X, Huo S, Chen F, Zou GZ* and Liang XJ*.Seedless Synthesis of High Aspect Ratio Gold Nanorods with High Yield. Journal of Materials Chemistry A. 2013. DOI: 10.1039/C3TA13905K.

  6. Zhao Y, Zhang X, Xue X, Li Z, Chen F, Li S, Kumar A, Zou G*, and Liang XJ* . High Throughput Detection of Human Neutrophil Peptides from Serum, Saliva and Tear by Anthrax Lethal Factor-Modified Nanoparticles. ACS Applied Materials & Interfaces. 2013. 11;5(17): 8267-8272.

  7. Li S.; Cao W.; Jin S.; Kumar A.; Liu J.; Zhang C.; Zou G.;Li F.; Liang XJ*. Near-Infrared Fluorescent Aptamer-templated Silver Nanoclusters Facile Synthesized for Cellular Imaging Applications. SCIENCE CHINA (E: Technological Sciences). 2013. In press.

  8. An F, Yang Y, Liu J, Ye J, Zhang J, Zhou M, Zhang X,* Zheng C, Liang XJ, Zhang X*. Reticuloendothelial System-Stealthy Dye-Albumin Nanocomplex as a Highly Biocompatible and Highly Luminescent Nanoprobe for Targeted In Vivo Tumor Imaging. RSC Adv., 2013, DOI: 10.1039/C3RA47058J.

  9. Lv P, Tang Z, Liang XJ, Guo M, and Han P.Spatially gradated segregation and recovery of circulating tumor cells from peripheral blood of cancer patients. Biomicrofluidics 2013 7(3): 034109

  10. Zhang XD, Chen J, Luo Z, Wu D, Shen X, Song SS, Sun YM, Liu PX, Zhao J, Huo S, Fan S, Fan F, Liang XJ, Xie J. Enhanced Tumor Accumulation of Sub-2 nm Gold Nanoclusters for Cancer Radiation Therapy. Adv Health Mater. 2013 Jul 22. doi: 10.1002/adhm.201300189.

  11. Sun Y, Cao W, Li S, Jin S, Hu K, Hu L, HuangY, GaoX, Wu Y*, Liang XJ*. Ultrabright and multicolorful fluorescence of Amphiphilic Polyethyleneimine polymerdots for efficiently combined imaging and therapy. Scientific Reports 2013. 3:3036.

  12. Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ*. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale. 2013, 5 (18), 8307 – 8325.

  13. Wei T, Liu J, Ma H, ChengQ, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang XJ *. Functionalized nanoscale micelles improve the drug delivery for cancer in vitro and in vivo. Nano Letter. 2013. 13(6):2528-2534.

  14. Ma X, Gong A, Xiang L, Chen T, Gao Y, Liang XJ, Shen Z* and Wu A* . Biocompatible composite nanoparticles with large longitudinal relaxivity for targeted imaging and early diagnosis of cancer. Journal of Materials Chemistry B. 2013.1:3419-3428.

  15. Zhang J, Yang K, Zhang H, Liang XJ. Application Status and Prospect of Carbon-Based Nanomaterials in the Biomedical Field.  Progress in Chemistry, 2013, 25(2): 397-408.

  16. Chen S, Zhang Q, Hou Y, Dai C, Zhan J*, and Liang XJ*. Nanomaterials in medicine and pharmaceuticals: nanoscale materials developed with less toxicity and more efficacies. European Journal of Nanomedicine. 2013. 5(2): 61–79.

  17. Hu L*, Sun Y, Li S, Wang X, Hu K, Wang L, Liang XJ, Wu Y*. Multifunctional carbon dots with high quantum yield for imaging and gene delivery. Carbon. 2014. 67: 508–513

  18. Zhang W, Cheng Q, Guo S, Lin D, Huang P, Liu J, Wei T, Deng L, Liang Z, Liang XJ*,, and Dong A. Gene Transfection Efficacy and Biocompatibility of Polycation/DNA Complexes Coated with Enzyme Degradable PEGylated Hyaluronic acid. Biomaterials. 2013. 34(27):6495-6503
  19. Huo S, Jin S, Zheng K, He S, Wang D & Liang, X.J*. Preparation and characterization of doxorubicin functionalized tiopronin-capped gold nanorods for cancer therapy. Chinese Science Bulletin. 2013. 58 (33):4072-4076.

  20. Kumar A, Zhang X, Liang, X.J*. Gold Nanoparticles: Emerging Paradigm for Targeted Drug Delivery System. Biotechnology Advances. 2013 (31):593-606.

  21. Pelaz B, Charron G, Pfeiffer C, Zhao Y, Fuente J, Liang, X.J, Parak W, and Pino P. Interfacing Engineered Nanoparticles with Biological Systems: Anticipating Adverse Nano-Bio Interactions. Small. 2013. 27(9):1573-1584.

  22. Wu S, Chen C, Shen X, Li G, Gao L, Chen A, Hou J and Liang XJ. One-pot synthesis, formation mechanism and near infrared fluorescent properties of hollow and porous a-mercury sulfide. CrystEngComm. 2013, 15, 4162-4166.

  23. Gil P, Aberasturi D, Wulf V, Pelaz B, Pino P, Zhao Y, Fuente J, Larramendi, Teófilo Rojo I, Liang, X.J, Parak W. The challenge to relate physico-chemical properties of colloidal nanoparticles to their cytotoxicity. Accounts of Chemical Research. 2013.46(3):743-749.

  24. Haque F, Li F, Wu H, Liang, X.J, and Guo P. Solid-state and biological nanopore for real-time sensing of single chemical and sequencing of DNA. Nano Today. 2013. 8(1): 56-74.

  25. Hu X, Hao X, Wu Y, Zhang J, Zhang X, Wang P, Zou G, Liang, X.J*. Multifunctional hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and pH dually response. Journal of Material Chemistry. B, 2013,1, 1109-1118.

  26. Cheng Q, Huang Y, Zheng H, Wei T, Zheng S, Huo S, Wang X, Du Q, Zhang X, Zhang H, Liang XJ, Wang C, Tang R*, Liang Z*.The effect of Guanidinylation of PEGylated Poly(2-aminoethyl methacrylate) on the Systemic Delivery of siRNA. Biomaterials. 2013.34(12):3120-3131.

  27. Jia L, Lu Y, Shao J, Liang XJ, Xu Y. Nanoproteomics: a new spout from emerging links between nanotechnology and proteomics. Trends in Biotechnology, 2013. Feb 31(2): 99-107.

  28. Yang K, Cao W, Hao X, Xue X, Zhao J, Liu J, Zhao Y, Meng J, Sun B, Zhang J, Liang, X.J*. Metallofullerene Nanoparticles Promote Osteogenic Differentiation of Bone Marrow Stromal Cells through BMP Signaling Pathway. Nanoscale. 2013, 5 (3), 1205 – 1212.

  29. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, Zhang J, He S and Liang, X.J*. Superior penetration and retention behavior of 50nm gold nanoparticles in tumor. Cancer Research, 2013 73:319-330.

  30. Meng J*, Liang, X.J, Chen X, Zhao Y. Biological characterizations of [Gd@C82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy. Integrative Biology. 2013. 5(1):43-47.

  31. Jin S, Ma X, Ma H, Zheng K, Liu J, Hou S, Meng J, Wang P, Wu X, Liang, X.J*. Surface Chemistry-Mediated Penetration and Gold Nanorods Thermotherapy in Multicellular Tumor Spheroids. Nanoscale. 2013, 5 (1), 143 – 146.

  32. Hua D, Zhang X, Zou G, Kumar A, Zhang X and Liang, X.J*. Long genomic DNA amplicons adsorption onto unmodified gold nanoparticles for colorimetric detection of Bacillus anthracis. Chemical Communication. 2013, 49(1): 51-53.

  33. Yang H, Sun C, Fan Z, Tian X, Yan L, Du L, YLiu, Chen C, Liang, X.J, Anderson GJ, Keelan JA, Zhao Y & Nie G. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Scientific Reports 2012, (2) : 847: 1-7.

  34. Ma X, Zhang L, Wang L, Xue X, Sun J, Wu Y, Zou G, Wu X, Wang P, Wamer W, Yin J, Zheng K, Liang, X.J*. Single-walled Carbon Nanotubes Alter Cytochrome C Electron Transfer and Modulate Mitochondrial Function. ACS Nano, 2012. Dec 21;6(12):10486-96.

  35. Meng J*, Yang X, Lee J, Liang, X.J, Wang C. Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism andFunction of Endothelial Cells. Current Drug Metabolism. 2012. 13(8):1123-1129.

  36. Han L, Zhao J, Zhang X, Cao W, Hua X, Zou G, Duan X, Liang, X.J*. Simple charge-reversal polymer assembly nanosystem with good biocompatibility for enhanced siRNA delivery and silencing. ACS Nano, 2012. 28; 6(8):7340-51.

  37. Liang, X.J*, Kumar A, Shi D, and Cui D. Nanostructures for Medicine and Pharmaceuticals. Journal of Nanomaterials. 2012. 7:1-2. (Editorial comment)

  38. Huang Y, He S, Cao W, Cai K and Liang, X.J*. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale. 2012, 4 (20), 6135 – 6149.

  39. Han L, Du L, Kumar A, Jia H, Liang, X.J*, Tian Q, Nie G and Liu Y. Inhibitory effects of trolox-encapsulated chitosan nanoparticles on tert-butylhydroperoxide induced RAW264.7 apoptosis. Biomaterials. 2012. 33(33):8517-28.

  40. Jiang Q, Song C, Nangreave J, Liu X, Lin L, Qiu D, Wang Z, Zou G, Liang, X.J, Yan H, Ding B. DNA Origami as a Carrier for Circumvention of Drug Resistance. JACS. 2012. 134 (32), pp 13396–13403.

  41. Ma M, Hao Y, Liu N, Yin Z, Wang L, Liang, X.J*, Zhang X*. A novel lipid-based nano-micelle of docetaxel: evaluated antitumor efficiency and biodistribution with optical imaging in vivo. In J Nanomedicine. 2012. 7: 3389-3398.

  42. Tan J.J., Liu C., Sun X.H., Cong X.J., Hu L.M., Wang C.X., and Liang, X.J*. Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase. Mini-Reviews in Medicinal Chemistry, 2012, 12(9):875-889.

  43. Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, Zhang X, Jin S, Gan Y, Wang P, He S, Zhang Xand Liang, X.J*. Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in vivo. ACS Nano. 2012. 6 (5), 4483–4493. Commented on News and Views. Nanomedicine (2012) 7(7), 945–948.

  44. Zhang X, Wu D, Shen X, Chen J, Sun Y, Liu P, Liang, X.J*. Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials. 2012. 33(27):6408-19.

  45. Wang L, Zhang L, Xue X, Ge Gand Liang, X.J*. Enhanced dispersibility and cellular transmembrane capability of single-walled carbon nanotubes individualised by polycyclic organic compounds as chaperon. Nanoscale, 2012. 4, 3983-3989.

  46. Liu, J, Ma, H., Wei, T. and Liang, X.J*.. CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chemical Communication. 2012. 48, 4869–4871

  47. Ma, H, Jiang, Q., Han, S.Y., Wu, Y., Li T., Wang D., Gan, Y.L., Zou, G.Y.*, and Liang, X.J.*. Multicellular Tumor spheroids (MCTSs) as an in vivo-like model for 3D Imaging of Chemotherapeutics and Nano Materials Penetration. Molecular Imaging, 2012. 11(6): 487-98.

  48. Huo, S.D., Ma, H.L., He, S.T. and Liang, X.J*. Controllable preparation of large size gold nanoparticles coated with tiopronin by seed-growth method. Journal of Chinese Electron Microscopy Society. 2012. 31(4):320-323.

  49. Liu Z and Liang, X.J*. Nano-Carbons as Theronostics. (Editorial comment). Theranostic. 2012, 2(3): 235-237. (Editorial comment)

  50. Ma, X.W, Wang, H., Jin, S.B., Wu, Y. *, Liang, X.J *.Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-poly (lactide)-1,2-dipalmitoyl-sn- glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. International Journal of Nanomedicine, 2012, 7: 1313-1328.

  51. Xue X and Liang, X.J *. Overcome drug efflux-based multidrug resistance by cancer nanotechnology. Chinese Journal of Cancer. 2012. 31(2). 100-109.

  52. Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S.B., Liu, J., Wei, T., Cao, W.P., Liang, X.J*. Ultra Small Gold Nanoparticles Fabricated with Therapeutic and Targeted Peptides for Cancer Treatment. Biomaterials 2012. 33(4): 1180-1189.

  53. Meng H, Xing G, Blanco E, Song Y, Zhao L, Sun B, Li X, Wang PC, Korotcov A, Li W, Liang XJ, Chen C, Yuan H, Zhao F, Chen Z, Sun T, Chai Z, Ferrari M, Zhao Y. Gadolinium Metallofullerenol Nanoparticle Inhibits Cancer Metastasis through Matrix Metalloproteinase Inhibition: Prison Instead of Poison Cancer Cells. Nanomedicine. 2012. 8: 136–146.

  54. Xue, X., You, S., Zhang, Q., Wu, Y., Zou, G.Z., Wang, P.C., Zhao, Y., Xu, Y., Jia, L., Zhang, X., Liang, X.J*. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Molecular Pharmaceutics, 2012, 9 (3): 634−644.

  55. Deng, H., Xu, Y., Liu, Y.H., Che, Z.J., Guo, H.L., Shan, S., Sun, Y., Liu, X., Huang, K., Ma, X.W., Wu, Y. and Liang, X.J*. Gold nanoparticles with asymmetric polymerase chain reaction for rapid colorimetric detection of DNA sequence. 2011. Analytical Chemistry, 2012, 2012, 84 (3): 1253–1258.

  56. Han, S.Y., Wang, H., Liang, X.J., Hu, L.M., Li, M., Wu, Y. Nanoparticle carriers based on copolymers of poly (L-aspartic acid co-L-lactide)-1,2-dipalmitoy l-sn-glycero-3- phosphoethanolamine for drug delivery. J Nanoparticle Research. (2011) 13:4371–4385

  57. Meng J., Xing J., Wang Y., Lu J., Zhao, Y., Gao X., Wang, PC, Jia L., Liang, X.J*. Epigenetic modulation of human breast cancer by Metallofullerene nanoparticles: in vitro analysis and in vivo treatment. Nanoscale. 2011 ( 3): 4713-4719

  58. Ma, X.W., Wu, Y., Jin, S.B., Tian.Y., Zhang, X.N., Zhao.Y., Yu, L. and Liang, X.J*. Gold Nanoparticles Induce Autophagosome Accumulation through Size-Dependent Nanoparticle Uptake and Lysosome Impairment. ACS Nano. 2011. 5 (11): 8629–8639.

  59. Kumar, A., Boruah, B.M., Liang, X.J*. Gold Nanoparticles: A promising nanomaterial for the diagnosis of Cancer and HIV-AIDS. Journal of Nanomaterials. 2011. 10: 1-17.

  60. Ma, X.W., Zhao, Y., Liang, X.J*. Theranostic Nanoparticles engineered for Clinic and Pharmaceutics. Accounts of Chemical Research. 2011. 44(10): 1114–1122

  61. Ma, X.W., Zhao, Y., Liang, X.J*. Nanodiamond delivery circumvents tumor resistance to doxorubicin. Acta Pharmacologica Sinica. 2011. 32: 543–544

  62. Sun, J.B., Li, Y., Liang, X.J*, Wang, P.C.*. Bacterial Magnetosome: a Novel Biogenetic Magnetic Targeted Drug Carrier with Potential Multi-functions. Journal of Nanomaterials. 2011, 8: 1-13

  63. Schneider, J., Grodsinki, P., Liang, X.J. Cancer nanotechnology research in the United States and China: cooperation to promote innovation. WIREs Nanomedicine and Nanobiotechnology, 2011. 3(5): 441-448.

  64. Sun C., Yang H., Yuan Y., Tian X., Wang L., Guo Y., Xu L., Lei J., Gao N., Anderson G., Liang, X.J; Chen C., Zhao Y.L., Nie G. J. Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging. JACS, 2011. 133(22): 8617-8624.

  65. Huang KY, He ST, Liu YL, He HY, Wang SS, Huo SD, Liang XJ*. Controlled synthesis of well-dispersed Au nanoparticles passivated by tiopronin. Science in China G. 2011, 41: 1036-1040.

  66. He, H., Ben, H., Liang, X.J*. Application of Nanotechnology for Development of Nanoadjuvants. Journal of Southeast University (Medical Science Edition), 2011, 30(1): 146-151.

  67. Guo, ST., Huang, YY., Zhang, WD., Wang, WW., Wei, T., Lin, DS., Xing, JF., Deng, LD., Du, Q., Liang, ZC., Liang, XJ *, Dong, A. Ternary Complexes of Amphiphilic Polycaprolactone-graft-Poly (N,N-dimethylaminoethyl methacrylate), DNA and Polyglutamic-graft-Poly(ethylene glycol) for Gene Delivery. Biomaterials; 2011, 324283-4292.

  68. Jia, L, Zhao, Y., Liang, X.J. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today, 2011. 6(1): 6-11.

  69. Wang, T., Zhang, C.*, Liang, X.J, Liang, W., Wu, Y. Hydroxypropyl- β-cyclodextrin Copolymers and Their Nanoparticles as doxorubicin Delivery System. Journal of Pharmaceutical Sciences 2011. 100(3): 1067-1079.

  70. Guo, S.T., Huang, Y., Wei, T., Wang, W.D., Wang, W.W., Lin, D., Zhang, X., Kumar, A., Du, Q., Xing, J., Deng, L., Liang, Z., Wang, P., Dong A., and Liang, X.J.* Amphiphilic and Biodegradable Methoxy Polyethylene glycol-block-(polycaprolactone-graft-poly (2-(dimethylamino)ethyl methacrylate)) as an Effective Gene Carrier. Biomaterials, 2011, 32: 879-889.

  71. Meng, J., Wang, DL., Wang, PC., Jia, L., Chen, C, Liang, XJ*. Biomedical Activities of Endohedral Metallofullerene Optimized for Pharmaceutics. Journal of Nanoscience and Nanotechnology. 2010, 10: 8610-8616.

  72. Xue, X., You, S., Liang, X.J*. Chemotherapeutic resistance of cancer and its related gene therapeutic drugs. Chinese Journal of Medicinal Chemistry. 2010,20 (5): 460-466

  73. Guo, S.T., Huang, Y., Jiang, Q., Sun, Y., Deng, L., Liang, Z., Du, Q., Xing, J., Zhao, Y., Wang, P., Dong A., and Liang, X.J.*. Enhanced Gene Delivery and siRNA Silencing by Gold Nanoparticles Coated with Charge-reversal Polyelectrolyte. ACS Nano. 2010. 4(9): 5505-5511.

  74. Korotcov A, Shan L, Meng H, Wang TX, Sridhar R, Zhao YL, Liang XJ, Wang PC. A Nanocomplex System as Targeted Contrast Agent Delivery Vehicle for Magnetic Resonance Imaging Dynamic Contrast Enhancement Study. Journal of Nanoscience and Nanotechnology. 2010, 10: 7545-7549.

  75. Ma, X., Che, Z., Liu, Y., Guo, T. and Liang, X.J*. Application of Electrophoresis in the Separation of Nanoparticles. Science in China: C. 2010. 40 (10): 1478-1486.

  76. Guo, S.T, Qiao, Y., Wang, W., He, H., Deng, L., Xing, J., Xu, J., Liang, X.J., and Dong A. Poly(ε-caprolactone)-graft-poly(2-(N, N-dimethylamino) ethyl methacrylate) Nanoparticles: pH Dependent Thermo-Sensitive Multifunctional Carriers for Gene and Drug Delivery. Journal of Materials Chemistry, 2010, 6935-6941.

  77. Wang, Y., LV, J., Ma, X., Wang, D., Ma, H., Chang, Y., Nie, G., Jia, L., Duan, X. and Liang, X.J*. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model. Current Drug Metabolism, 2010, 11: 507-515.

  78. Liang, X.J. *, Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P. C., Zhao, Y., Gao, X., Sun, B., Chen, C., Xing, G., Shen, D., Gottesman, M. M., Wu, Y., Yin, J.J., Jia, L. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proceedings of the National Academy of Sciences of the United States of America. Proc Natl Acad Sci U S A. 2010. 107(16):7449-7454.

  79. Ma, H., Wang, P C, Qian, F. and Liang, X.J*. Biological Effects of Nanomaterials and Drugs Measured by the Small-animal SPECT/CT Imaging System IN VIVO. Acta Biophysica Sinica. 2010. 26(8): 691-701.

  80. Meng, H., Xing, G., Sun, B., Zhao, F., Lei, H., Li, W., Song, Y., Chen, Z., Yuan, H., Xia, W., Jing, L., Chen, C., Liang, X.J., Zhang, N., Chai, Z, Zhao, Y. Potent angiogenesis inhibition by particulate form of fullerene Derivatives. ACS Nano 2010, 25; 4(5):2773-83.

  81. Ma, X.W., Wang, D., Wu, Y., Ho, RJY, Jia, L., Guo, P., Hu, L., Xing, G., Zeng, Y., Liang, X.J*. AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. AAPS J. 2010, 12(3):272-278.

  82. Xing, J, Deng, L, Guo, S, Dong, A, and Liang, X.J*. Polycationic Nanoparticles as Nonviral Vectors Employed for Gene Therapy In Vivo. Mini-Reviews in Medicinal Chemistry. 2010, 10(2):126-37.

  83. Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L and Liang, X.J*. Therapeutic Strategies Underpinning the Development of Novel Techniques for the Treatment of HIV Infection. Drug Discovery Today. 2010. 15(5): 186-197.

  84. Jia, L., Zhao, Y. and Liang, X.J. Current Evaluation of the Millennium Phytomedicine-­Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine. Current Medicinal Chemistry, 2009, 16, 2924-2942.

  85. Wang, P.C., Blumenthal, R.P., Zhao, Y, Schneider, J.A., Miller, N., Grodzinski, P., Gottesman, M.M., Tinkle, S., Wang, K., Wang, C., Liang, X.J*. Building Scientific Progress without Borders: Nanobiology and Nanomedicine in China and the U.S. Cancer Research. 2009, 69: 5294-5295.

  86. Wang, Y.Z., Huang, B., Lv J., and Liang XJ*. Current Status Of Nanotechnology Applied In Biomedicine. Acta Biophysica Sinica 2009, 25(3): 168-174.

  87. Wan, L.X., Liang, XJ and Huang YG. Characterization of the ATPase activity of a novel chimeric protein consisting of two nucleotide binding domains of MRP1. Archives of Biochemistry and Biophysics. 2009, 485(2):102-108.

  88. Wang YZ, Duan XL, Li YF, Liang XJ*. Multidrug Resistance Mediated by Half ABC Transporter ABCG2. Prog. Biochem. Biophys. 2009, 36(12): 1523-1529.

  89. Yin, JJ., Lao, F., Fu, PP., Wamer WG., Zhao, YL, Wang, PC., Qiu, Y., Sun, B, Xing G, Dong, J., Liang, XJ*, Chen, C. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials. 2009, 30(4):611-621 *

  90. Wang, P, Shan, L., Wang, S.P., Korotcov, A and Liang, XJ. Transferrin Liposome Nanoparticle (TfNIR-LipNBD-Magnevist) – A Tumor Targeting MRI Contrast Agent. Acta Biophysica Sinica. 2008, 24(4):315-322.

  91. Liang, X.J. *, Chen, C.Y., Zhao, Y.L., Jia, L., Wang, PC. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials. Current Drug Metabolism. 2008, Oct; 9(8):697-709.

  92. Yin, JJ., Lao, F., Meng, J., Fu, PP., Zhao, YL, Xing G, Gao X, Sun, B, Wang, PC., Chen, C, Liang, XJ*. Inhibition of Tumor Growth by Polyhydroxylated Endohedral Metallofullerenol Nanoparticles Optimized as Reactive Oxygen Species Scavenger. Molecular Pharmacology. 2008, 74: 1132-1140.

  93. Liang, X. J.*, Shen, D.W., Yin, J.J., Aszalos, A., and Gottesman, M. M. SIRT1 contributes to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Molecular Cancer Research. 2008, 6(9):1499-1506.

  94. Liang, X.J., Choi, Y., Sackett, D.L. and Park, J.K. Inhibition of stathmin enhances CCNU blocking glioma cell migration and invasion. Cancer Research. 2008, 68(13):5267-5272.

  95. Gao, X, Xing G, Chu, W, Liang, X.J., Zhao, Y, Jing, L., Yuan, H, Cui, Y, Dong J. The Growth of Complex Nanostructures: Synergism of Dipolar Force and Stacking-Defect in Anisotropic Self-assembly, Advanced Materials. 2008, 20, 1794–1798.

  96. Liang, X.J.,Yin, J.J., Taylorc, B, Wincovitch S M., Garfield, S., Shen D.W., Gottesman, M.M. and Aszalose A. Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. Cancer Chemotherapy and Pharmacology. 2008, 62(6):977-84.

  97. Hall MD, Okabe M, Shen, DW, Liang, XJ, and Gottesman, MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology. 200848: 495-535.

  98. Wu WW, Wang G, Liang XJ, Park JK, Shen RF. Covalent modification of stathmin by CCNU determined by FTMS analysis of modified proteins and tryptic peptides. Biochem Biophys Res Commun. 2008; 367(1):7-13.

  99. Ngo.T.B*, Peng T., *, Liang X.J *., Akeju O., Pastorino S., Zhang W., Fine H.A., Maric D., Wen P.Y., Girolami U.D., Black P.M., Wu W., Shen R.F., Kang D.W., and Park J.K. The 1p encoded protein stathmin modulates the response of malignant gliomas to nitrosoureas. Journal of National Cancer Institute. 2007, 99: 639-652. [*: Equal contribution]

  100. Liang, X. J. and Aszalos A. Multidrug transporters as drug targets. Current Drug Targets. 2006, 7 (8): Aug 911-921.

  101. Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R. and Gottesman, M. M. Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells . Cancer Research. 2006, 66 (4): Feb 15; 2346-2353.

  102. Liang, X. J., Taylor B, Cardelli C, Yin JJ, Annereau JP, Garfield SH, Wincovitch S, Szakacs G, Gottesman, M. M and Aszalos A. Different roles for K+ channels in cisplatin resistant cell lines Argue Against a Critical Role for These Channels in Cisplatin Resistance. Anticancer Research. 2005, 25(6B): 4113-4122.

  103. Liang, X. J., Shen, D. W., Chen G. K., Wincovitch S. M., Garfield, S., and Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. Journal of Cellular Physiology. 2005, 202 (3): 635-641.

  104. Liang, X.J, Shen, D.W, and Gottesman, M.M. Down-regulation and altered localization of -catenin in cisplatin-resistant adenocarcinoma cells. Molecular Pharmacology. 2004 65 (5): 1217-1224.

  105. Liang, X.J, Shen, D.W, and Gottesman, M.M. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry. 2004 (98) 1599-1606.

  106. Liang, X.J, Yin, J.J., Zhou, J.W., Wang, P. C., Taylor, B., Cardarelli, C., Kozar, M, Forte, R., Aszalos, A. and Gottesman, M. M.: Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research. 2004, 293: 283-291.

  107. Liang, X. J., Shen, D. W., Garfield, S., and Gottesman, M. M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistanct cancer cell lines. Cancer Research. 2003, 63: 5909-5916.

Book Chapters:

  1. Gottesman, M.M., Hall, M.D., Liang, X.J., and Shen, D.W.: Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In Bonetti, A. Leone, R. Muggia, F. Howell, S.B. (Eds.): Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Humana Press, Totowa, New Jersey, 2009, 83-88.

  1. Liang, X.J., Chen, C.Y., Zhao, Y.L., Wang, P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer Series: Methods in Molecular Biology , Zhou, Jun (Ed.), Humana Publisher, New York, 2010; 596: 467-488.

  1. Jian Jun Tan, Chang Liu, Li Ming Hu, Cun Xin Wang and Xing-Jie Liang. The State of the Science: a 5-Year Review on the Computer-Aided Design for Global Anti-AIDS Drug Development. HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Edited), 2011, INTECH open access publisher, ISBN978-953-307-343-9. 2011, 25-46.

  1. Liang, X.J. Editing “Nanopharmaceuticals: Potential Application of Nanomaterials. (approx. 800pp) World Scientific Publication Press, New Jersey, 2012. ISBN: 978-981-436-866-7.

Community service:
Chinese Society of Biophysics; Chinese Pharmaceutical Association;American Association for Cancer Research;American Society for Cell Biology;Association of the International Union against Cancer;International Society of Nanomedicine

Commitment to research the situation:

1.“International Collaborative Nano-program of China and Finland”, 2008-2010.  2.“973 Program (National Key Science and Technology Plan)” of Chinese Ministry of Science and Technology, 2009-2013, Chief Scientist. 3. National Natural Science Foundation of China (Gerneral Program),2010-2013,  Principal Investigator.  4. “863” program (National Program of Gene Therapy) of Chinese Ministry of Science and Technology, 2012-2016,Program Investigator. 5. National Natural Science Foundation of China (National Distinguished Young Scholars Program),2013-2016,  Principal Investigator.